Article
Avian metapneumovirus SH gene end and G protein mutations influence the level of protection of live-vaccine candidates.
The Journal of general virology - 1 Jun 2007
Naylor Clive J, Ling Roger, Edworthy Nicole, Savage Carol E, Easton Andrew J
Abstract excerpt
A prototype avian metapneumovirus (AMPV) vaccine (P20) was previously shown to give variable outcomes in experimental trials. Following plaque purification, three of 12 viruses obtained from P20 failed to induce protection against virulent challenge, whilst the remainder retained their protective capacity. The genome sequences of two protective viruses were identical to the P20 consensus, whereas two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
